No beneficial effect of interferon-gamma treatment in 2 human immunodeficiency virus-infected patients with Mycobacterium avium complex infection.

Abstract

Two human immunodeficiency virus-infected patients with refractory disseminated Mycobacterium avium complex infection were treated with recombinant interferon-gamma (IFN-gamma) given subcutaneously for 3 and 4 months, respectively. Although both patients demonstrated some clinical improvement initially, IFN-gamma therapy did not produce sustained benefit.

• Authors: F N Lauw, J T van Der Meer, J de Metz, S A Danner, T van Der Poll
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 32 Issue 4 Pg. e81-2 (Feb 15 2001) ISSN: 1058-4838 [Print] United States
• PMID: 11181141 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Interferon-gamma

Topics

• AIDS-Related Opportunistic Infections (drug therapy, microbiology)
• Adult
• Female
• Humans
• Interferon-gamma (therapeutic use)
• Male
• Mycobacterium avium Complex
• Mycobacterium avium-intracellulare Infection (drug therapy, microbiology)
• Treatment Outcome